GlaxoSmithKline ($GSK) will bring its cleaned-up marketing and sales focus to India by following steps it took in China as it looks to shake off the damage its reputation took with the massive $489 million fine it paid last year for bribing doctors and hospitals to buy its drugs.
The Times of India, in an interview with Annaswamy Vaidheesh, vice-president, South Asia & managing director of GSK Pharmaceuticals India, said the steps are based on a new healthcare marketing code covering doctors and the company's field staff.
That means ending sales target incentives for its 3,000 customer reps, as well as speaking engagement payments to doctors.
Outgoing CEO Andrew Witty has spoken repeatedly since the China bribery scandal about the need to reform almost every aspect of the drug industry sales model, and to focus on volumes and payer negotiations over and above the traditional, high-pressure sales efforts aimed at doctors.
In China, the company last year eliminated sales-based compensation incentives for reps and doctor speaking fees, while at the same time running aggressive compliance operations in-house.
GSK has taken a hard hit on sales in China, though executives in the firm contend that the actions have reshaped relations with China's policymakers and will pay off in the long run.
In India however, government reimbursement and insurance lag China with most patients paying out-of-pocket--making doctors, clinics and hospitals an even more important driver of sales.
One way GSK plans to tackle sales in India is through a "Patient Focused Selling" program, which has already been in the works through a pilot study that relies heavily on digital outreach, including to sales reps "in a more systematic and consistent manner," and a push into rural markets, Vaidheesh told the newspaper.
Read the rest here